Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9901A-004 |
Labetuzumab
IMMU-14,hMN-14,IMMU-100 |
||
Labetuzumab (hMN-14) 是一种人源化抗癌胚抗原 (CEA) 单克隆抗体,具有抗癌活性,可抑制肿瘤生长,可用于研究甲状腺癌和结直肠癌 (CRC)。 | |||
T25593 |
Labetuzumab govitecan
IMMU-130,Labetuzumab-SN38,hMN14-SN38,IMMU130,IMMU 130 |
Others | Others |
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | |||
T17732 | CL2A | Others | Others |
CL2A is a pH-sensitive, cleavable PEG8- and triazole-containing PABC-peptide-mc linker, characterized by its ability to induce a bystander effect. It forms a disulfide bond with an antibody at a cysteine residue. Labetuzumab govitecan utilizes this linker for its drug conjugation[1]. |